Ferdinandos Skoulidis, MD,PHD

Trials

Studies that name Ferdinandos Skoulidis, MD,PHD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:46 UTC. Open this list on ClinicalTrials.gov

• Ph2
  NCT05118854 · A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation

  M.D. Anderson Cancer Center · active not recruiting · Lung Cancer · principal investigator
• Ph1/Ph2
  NCT03225664 · Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced

  M.D. Anderson Cancer Center · active not recruiting · Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8 · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 12:46 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• Personalizing NSCLC Therapy: Exploiting KRAS activated pathways
  R01CA155196 · NCI · YALE UNIVERSITY · PI Roy S Herbst, Vassiliki Papadimitrakopoulou · fiscal years 2011 to 2015
  Named on NCT03225664